Shell Asset Management’s Puma Biotechnology PBYI Stock Holding History

Shell Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-48,702	Closed	-$341K	–	1409
2021 Q3	$341K	Sell	48,702 -2,090	-4%	-$15.6K	0.01%	1029
2021 Q2	$466K	Buy	50,792 +2,750	+6%	+$27.9K	0.01%	946
2021 Q1	$467K	Buy	48,042 +15,714	+49%	+$175K	0.01%	883
2020 Q4	$332K	Buy	+32,328	New	+$327K	0.01%	960
2015 Q3	–	Sell	-900	Closed	-$105K	–	890
2015 Q2	$105K	Buy	+900	New	+$163K	﹤0.01%	853

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Shell Asset Management's PBYI Position: Q4 2021 in Review

Shell Asset Management sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 48,702 shares — an estimated $341K sold.

Shell Asset Management first reported a position in PBYI in Q2 2015 and held it in 5 quarters. The position peaked at $467K in Q1 2021. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

Shell Asset Management reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
Shell Asset Management sold 48,702 Puma Biotechnology shares in Q4 2021, an estimated $341K.
Shell Asset Management first reported a position in Puma Biotechnology in Q2 2015 and held it in 5 quarters.
Shell Asset Management's Puma Biotechnology position peaked at $467K in Q1 2021.
102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Shell Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.